Document Detail

CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis.
MedLine Citation:
PMID:  16320722     Owner:  NLM     Status:  MEDLINE    
Biomarkers that allow the identification of patients with multiple sclerosis (MS) with an insufficient response to immunomodulatory treatment would be desirable, as currently available treatments are only incompletely efficacious. Previous studies have shown that the expression of CD25, CD26 and CCR5 on T cells is altered in patients with active MS. We studied the expression of these molecules by flow cytometry in patients followed for six months during immunomodulatory treatment. In interferon (IFN)-beta-treated patients, we found that the hazard ratio for developing an attack was 28 in patients with CD26 + CD4 + T cell counts above median, and this risk was independent of the risk conferred by neutralizing anti-IFN-beta antibodies. CD26 + CD4 + T cell counts may identify patients with MS at increased risk of attack during treatment with IFN-beta.
F Sellebjerg; C Ross; N Koch-Henriksen; P Soelberg S?rensen; J L Frederiksen; K Bendtzen; T L S?rensen
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  11     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-02     Completed Date:  2006-02-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  641-5     Citation Subset:  IM    
The MS Clinic, Copenhagen University Hospital, Glostrup, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / administration & dosage*
Antigens, CD26 / metabolism
Antigens, CD4 / metabolism
Biological Markers
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes / cytology*,  immunology,  metabolism
CD8-Positive T-Lymphocytes / cytology,  immunology,  metabolism
Flow Cytometry
Interferon-beta / administration & dosage*
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy*,  epidemiology,  immunology*
Proportional Hazards Models
Receptors, CCR5 / metabolism
Receptors, Interleukin-2 / metabolism
Risk Factors
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Antigens, CD4; 0/Biological Markers; 0/Receptors, CCR5; 0/Receptors, Interleukin-2; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta; EC, CD26

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multiple sclerosis management for low-income minorities.
Next Document:  Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-re...